ESR1 and breast cancer: Wardell et al. [37] tested the activity of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib administered as both monotherapy or in combination with the SERM bazedoxifene, in PDX models derived from patients with ER+ endocrine-resistant BC.